id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-2357-0018,FDA,FDA-2020-P-2357,Response Letter from FDA CFSAN to Keller and Heckman LLP,Other,Agency Response,2021-12-17T05:00:00Z,2021,12,2021-12-17T05:00:00Z,,2021-12-17T13:56:30Z,,0,0,0900006484ed1c81
FDA-2020-P-2357-0007,FDA,FDA-2020-P-2357,Reference 2_Augustin_2015,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T13:58:55Z,,0,0,0900006484ec9d4e
FDA-2020-P-2357-0010,FDA,FDA-2020-P-2357,Reference 5_Larson_2021,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:17:59Z,,0,0,0900006484ecb7ae
FDA-2020-P-2357-0006,FDA,FDA-2020-P-2357,Reference 1_Akeo_2002,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T13:56:30Z,,0,0,0900006484ec9d4d
FDA-2020-P-2357-0013,FDA,FDA-2020-P-2357,Reference 8_Ross_1983,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:22:51Z,,0,0,0900006484ecb7b1
FDA-2020-P-2357-0008,FDA,FDA-2020-P-2357,Reference 3_Bhat_2013,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:03:07Z,,0,0,0900006484ec9d4f
FDA-2020-P-2357-0017,FDA,FDA-2020-P-2357,Reference 12_Wolever 2019,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:30:24Z,,0,0,0900006484ecb7b5
FDA-2020-P-2357-0016,FDA,FDA-2020-P-2357,Reference 11_Uebelhack_2020,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:28:55Z,,0,0,0900006484ecb7b4
FDA-2020-P-2357-0015,FDA,FDA-2020-P-2357,Reference 10_Torres_2006,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:27:51Z,,0,0,0900006484ecb7b3
FDA-2020-P-2357-0014,FDA,FDA-2020-P-2357,Reference 9_Sharma_1985,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:23:52Z,,0,0,0900006484ecb7b2
FDA-2020-P-2357-0005,FDA,FDA-2020-P-2357,Reference List_12-14-21,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T13:56:43Z,,0,0,0900006484ec9d4c
FDA-2020-P-2357-0011,FDA,FDA-2020-P-2357,Reference 6_Nasir_2016,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:21:01Z,,0,0,0900006484ecb7af
FDA-2020-P-2357-0012,FDA,FDA-2020-P-2357,Reference 7_Pouteau_2010,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:21:54Z,,0,0,0900006484ecb7b0
FDA-2020-P-2357-0009,FDA,FDA-2020-P-2357,Reference 4_Campbell_1997,Supporting & Related Material,Background Material,2021-12-15T05:00:00Z,2021,12,,,2021-12-15T14:04:08Z,,0,0,0900006484ecb7ad
FDA-2020-P-2357-0004,FDA,FDA-2020-P-2357,180 day Interim Response Letter from FDA CFSAN to Keller and Heckman LLP,Other,Response(s),2021-07-06T04:00:00Z,2021,7,2021-07-06T04:00:00Z,,2021-07-06T12:49:09Z,,0,0,0900006484bd1c5d
FDA-2020-P-2357-0001,FDA,FDA-2020-P-2357,"Citizen Petition from Keller and Heckman LLP on behalf of Nexira, Alland & Robert and Importers Service Corporation",Other,Citizen Petition,2020-12-30T05:00:00Z,2020,12,2020-12-30T05:00:00Z,,2021-12-17T13:56:39Z,,0,0,09000064849ce2e5
FDA-2020-P-2357-0002,FDA,FDA-2020-P-2357,"Acknowledgment Letter from FDA DMS to Keller and Heckman LLP n behalf of Nexira, Alland & Robert, and Importers Service Corporation",Other,Acknowledgement Letter/Receipt,2020-12-30T05:00:00Z,2020,12,2020-12-30T05:00:00Z,,2020-12-30T13:41:28Z,,0,0,09000064849ce2e6
FDA-2020-P-2357-0003,FDA,FDA-2020-P-2357,"Appendix I Uebelhack re Citizen Petition from Keller and Heckman LLP on behalf of Nexira, Alland & Robert and Importers Service Corporation",Supporting & Related Material,Background Material,2020-12-30T05:00:00Z,2020,12,,,2020-12-30T13:41:37Z,,0,0,09000064849ce2e9